RXII
RXi Pharmaceuticals Corporation
NasdaqCM
People also watch:GALECYTROPXACYCCRNN
2.480.08 (3.34%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close2.40
Open2.44
Bid2.47 x 100
Ask2.55 x 100
52wk Range1.26 - 6.49
Day's Range2.41 - 2.64
Volume57,333
Avg Vol (3m)74,776
As of 1:05 PM EDT. NasdaqCM Real Time Price. Market open.
  • Capital Cube7 days ago

    ETF’s with exposure to RXi Pharmaceuticals Corp. : July 20, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to RXi Pharmaceuticals Corp.Here are 5 ETF’s with the largest exposure to RXII-US. Comparing the performance and risk of RXi Pharmaceuticals Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us […] (Read more...) The post ETF’s with exposure to RXi Pharmaceuticals Corp. : July 20, 2016 appeared first on CapitalCube.

  • Capital Cube2 months ago

    RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016

    Click here to see latest analysisRXi Pharmaceuticals Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of RXi Pharmaceuticals Corp. – WaferGen Bio-systems, Inc., Neuralstem, Inc., Heron Therapeutics Inc and Histogenics Corp. (WGBS-US, CUR-US, HRTX-US and HSGX-US) that have also reported for this period.HighlightsSummary numbers: […] (Read more...) The post RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.